IN2014DN08927A - - Google Patents

Info

Publication number
IN2014DN08927A
IN2014DN08927A IN8927DEN2014A IN2014DN08927A IN 2014DN08927 A IN2014DN08927 A IN 2014DN08927A IN 8927DEN2014 A IN8927DEN2014 A IN 8927DEN2014A IN 2014DN08927 A IN2014DN08927 A IN 2014DN08927A
Authority
IN
India
Prior art keywords
sbv
ruminants
relates
viremia
malformations
Prior art date
Application number
Inventor
Veljko Nikolin
Konrad Stadler
Axel Lischewski
Alexander Brix
Jeffrey P Knittel
Katharina Hedwig Toepfer
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of IN2014DN08927A publication Critical patent/IN2014DN08927A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12061—Methods of inactivation or attenuation
    • C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia the transmission and clinical symptoms in particular malformations in newborn ruminants such as cattle sheep and goats induced by SBV.
IN8927DEN2014 2012-06-01 2013-05-29 IN2014DN08927A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170631 2012-06-01
EP13157875 2013-03-05
PCT/US2013/043146 WO2013181270A1 (en) 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN08927A true IN2014DN08927A (en) 2015-05-22

Family

ID=48607368

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8927DEN2014 IN2014DN08927A (en) 2012-06-01 2013-05-29

Country Status (17)

Country Link
US (2) US9370562B2 (en)
EP (1) EP2855513B1 (en)
JP (1) JP6250649B2 (en)
CN (1) CN104350066B (en)
AR (1) AR091240A1 (en)
AU (1) AU2013267453C1 (en)
BR (1) BR112014029515A2 (en)
CA (1) CA2872961A1 (en)
DK (1) DK2855513T3 (en)
EA (1) EA034543B1 (en)
ES (1) ES2617351T3 (en)
IN (1) IN2014DN08927A (en)
MX (1) MX363044B (en)
PL (1) PL2855513T3 (en)
SG (1) SG11201407619SA (en)
UY (1) UY34840A (en)
WO (1) WO2013181270A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2855513B1 (en) 2012-06-01 2016-12-07 Boehringer Ingelheim Vetmedica GmbH Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
WO2013178711A1 (en) 2012-06-01 2013-12-05 Boehringer Ingelheim Vetmedica Gmbh Genomic sequences of schmallenberg virus and uses thereof
WO2014164697A1 (en) * 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
CN104232587B (en) * 2014-09-02 2016-08-17 中国检验检疫科学研究院 Cell line and the application thereof of Maron shellfish lattice virus nucleocapsid albumen is executed in stable expression
CN120758460A (en) * 2025-07-04 2025-10-10 中国兽医药品监察所 Pseudovirus of Schmallenberg virus and its application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811736B2 (en) * 1986-08-07 1996-02-07 財団法人化学及血清療法研究所 Cattle epidemic fever, Ibaraki disease, Akabane disease 3 types inactivated vaccine
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
WO2008112707A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents
EP2062594A1 (en) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
EP2855513B1 (en) 2012-06-01 2016-12-07 Boehringer Ingelheim Vetmedica GmbH Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
WO2013178711A1 (en) 2012-06-01 2013-12-05 Boehringer Ingelheim Vetmedica Gmbh Genomic sequences of schmallenberg virus and uses thereof

Also Published As

Publication number Publication date
US9872897B2 (en) 2018-01-23
CN104350066A (en) 2015-02-11
AU2013267453A1 (en) 2014-11-13
ES2617351T3 (en) 2017-06-16
AU2013267453C1 (en) 2017-08-10
JP2015519367A (en) 2015-07-09
MX2014014521A (en) 2015-02-24
BR112014029515A2 (en) 2017-07-25
EP2855513B1 (en) 2016-12-07
EA201401352A1 (en) 2015-05-29
EP2855513A1 (en) 2015-04-08
AR091240A1 (en) 2015-01-21
SG11201407619SA (en) 2014-12-30
EA034543B1 (en) 2020-02-19
UY34840A (en) 2013-12-31
DK2855513T3 (en) 2017-03-13
AU2013267453B2 (en) 2017-04-06
JP6250649B2 (en) 2017-12-20
US9370562B2 (en) 2016-06-21
CN104350066B (en) 2018-06-19
CA2872961A1 (en) 2013-12-05
PL2855513T3 (en) 2017-05-31
US20130323277A1 (en) 2013-12-05
WO2013181270A1 (en) 2013-12-05
US20160250317A1 (en) 2016-09-01
MX363044B (en) 2019-03-06

Similar Documents

Publication Publication Date Title
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
PH12016500773A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2014DN09173A (en)
PH12016500868A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
MX387277B (en) COMPOSITIONS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
MX2017010908A (en) Bivalent swine influenza virus vaccine.
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
IN2014DN08927A (en)
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX2013003245A (en) Bvdv vaccine.
UY34841A (en) INFECTIOUS VIRUS OF SCHMALLENBERG OF cDNA CLONATES AND ITS USES
GB2515440A (en) Vesicular formulations
EA201591095A1 (en) PROTEIN SLURP-1 FOR USE IN THE TREATMENT OF EYE DISEASES
EA201390452A1 (en) VACCINE
TR201200215A2 (en) Improved pharmaceutical formulations.
UA71871U (en) Method for diagnostics of effectiveness of antibiotic therapy in patients with lime-boreliosis